Pro 2013-004 (Jianfeng Group's First Extraordinary Shareholders' Meeting in 2013)
Release time:
2020-08-05
Stock Abbreviations: Jianfeng Group Stock Code: 600 66 8 No: pro 20 13 -0 04
Zhejiang Jianfeng Group Co., Ltd.
Resolution Announcement of the First Extraordinary General Meeting of Shareholders in 2013
The Board of Directors and all directors of the Company guarantee that the contents of this announcement do not contain any false records or misleading statements or material omissions, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents . |
Important Content Note:
1 , No Rejection or Modification of Proposals at this Meeting;
2 , no new proposal submitted for vote at this meeting.
1. Meeting and Attendance
Zhejiang Jianfeng Group Co., Ltd. The first extraordinary shareholders' meeting in 2013 was held on the spot on January 22, 2013 at Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province. The notice of this meeting was published in china securities journal and shanghai securities news on January 5, 20 13. The meeting was convened by the board of directors of the company and presided over by Mr. Jiang Xiaomeng, chairman of the board of directors.
There were 8 shareholders and shareholder representatives, representing 55719117 shares, accounting for 16.19 of the company's total share capital. Some directors, supervisors and senior executives of the company attended the meeting, and the company's legal counsel attended and witnessed the meeting. The convening of the meeting, held in line with the company law, the articles of association of the company.2. Proposal Review
This meeting deliberated and passed the following proposals by secret ballot and item by item:
1
, "Proposal on the Company's Compliance with the Conditions for Issuing Corporate Bonds"
Voting Results: Agree55719117 Shares, 100 per cent of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;opposed 0 shares, accounting for 0% of the voting shares present at the meeting.
2
and reviewed and approved the Proposal on Issuing Corporate Bonds Item by Item;
2.Issue Scale
Voting Result: Agreed55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
2.
2 Placing Arrangement to Original Shareholders of the Company
Voting Results: Agree to55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;opposes 0 shares, 0% of the number of voting shares present.
2.
3 Bond Term
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;Opposes 0 Shares, 0% of the number of voting shares present.
2.
4 Bond Interest Rate and Determination Method
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;Opposes 0 Shares, 0% of the number of voting shares present.
2.
5 Issuance Method
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;Opposes 0 Shares, 0% of the number of voting shares present.
2.
6 Issuing Object
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;Opposes 0 Shares, 0% of the number of voting shares present.
2.7
Guarantee Arrangement
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
2.8
Use of Funds Raised
Voting Results: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
2.9
Bond Issuance Listing
Voting Results: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
2.10
Resolution Validity Period
Voting Results: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
3
and "Proposal on Requiring the General Meeting of Shareholders of the Company to Authorize the Board of Directors and its Authorized Persons to Fully Handle Matters Related to the Issuance of Corporate Bonds"
Voting Results: Agree to55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
4
, "Proposal on Requiring the General Meeting of Shareholders of the Company to Authorize the Board of Directors to Take Repayment Safeguard Measures in the Case of Expected Failure to Pay the Bond principal and Interest on Time or Failure to Pay the Bond principal and Interest on Time"
Voting Result: Agree to55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
3. Lawyer's Witness
Lawyers Chen Xiongwu and Zuo Wenhui of Zhejiang Yijian Law Firm witnessed the shareholders' meeting on the spot and issued legal opinions, believing that: "
Zhejiang Jianfeng Group Co., Ltd. the convening and convening procedures of the first extraordinary general meeting of shareholders in 2013 , the qualifications of the participants, the proposals and voting procedures of this general meeting of shareholders, etc., all comply with laws, Regulations and the relevant provisions of the" Articles of Association ", the Resolution of this general meeting of shareholders is legal and valid. "
4. Reference Document Catalogue1
, "Resolution of the First Extraordinary General Meeting of Zhejiang Jianfeng Group Co., Ltd. in 2013" signed and confirmed by the participating directors
2, Zhejiang Yijian Law Firm "Law on the First Extraordinary General Meeting of Zhejiang Jianfeng Group Co., Ltd. in 2013 opinion .
hereby announceZhejiang Jianfeng Group Co., Ltd.
Board of Directors
January 22, 2013
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page